A case of metastatic thyroid cancer from renal cell cancer with tumor thrombus in the internal jugular vein

Choonpa Igaku ◽  
2008 ◽  
Vol 35 (5) ◽  
pp. 577-578
Author(s):  
Eriko TOHNO ◽  
Ei UENO ◽  
Tohru YASHIRO
Keyword(s):  
Thyroid Cancer ◽  
Internal Jugular Vein ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Jugular Vein ◽  
Cell Cancer ◽  
Metastatic Thyroid Cancer

scholarly journals Diffuse thyroid metastases and bilateral internal jugular vein tumor thrombus from renal cell cancer

2016 ◽  
Vol 11 (4) ◽  
pp. 434-437
Author(s):  
Priyanka Jha ◽  
Mallika Shekhar ◽  
Jennifer Wan ◽  
Carina Mari-Aparici
Keyword(s):  
Internal Jugular Vein ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Jugular Vein ◽  
Cell Cancer ◽  
Thyroid Metastases

NAXIVA: A phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer (RCC) with venous invasion.

2021 ◽  
Vol 39 (6_suppl) ◽  
pp. 275-275
Author(s):  
Grant D. Stewart ◽  
Sarah J. Welsh ◽  
Stephan Ursprung ◽  
Ferdia Gallagher ◽  
Iosif Mendichovszky ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Surgical Approach ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Response Rate ◽  
Clear Cell ◽  
Cell Cancer ◽  
Surgical Morbidity ◽  
Venous Tumor Thrombus ◽  
Extent Of Surgery

275 Background: Venous tumor thrombus (VTT) extension occurs in 4-15% cases of renal cell cancer (RCC). The Mayo classification distinguishes 4 levels of VTT extension between the renal vein and supradiaphragmatic inferior vena cava (IVC). Although surgery is performed with curative intent, mortality is high (5-15%) with complications increasing with the level of the VTT. 5-year survival rates are poor; ~40-65% in non-metastatic RCC. It is hypothesised that neoadjuvant targeted therapy could downstage the VTT reducing the extent of surgery, leading to reduced surgical morbidity and mortality, and increased survival. However, level I or II evidence is lacking. NAXIVA provides the first level II evidence in this patient group, assessing the response of VTT to axitinib. Extensive translational sampling will provide in depth interrogation of VTT (using genomics, proteomics, immunophenotyping and metabolomics) to examine the role of the tumor microenvironment of VTT and response to axitinib. Methods: NAXIVA was a single arm, single agent, multi-center phase 2 feasibility study of axitinib in patients with both metastatic and non-metastatic clear cell RCC prior to nephrectomy and thrombectomy. A Simon two stage minimax design was adopted and the trial designed for adequate power to distinguish a <5% from a >25% improvement in the Mayo VTT level. 21 patients were recruited over a 24 month period between 15/Dec/2017 and 06/Jan/2020 at 5 sites across the UK. Patients were treated with 8 weeks of axitinib (starting dose 5mg bd, increasing to 10mg bd as tolerated) prior to planned surgery. The primary endpoint was the percentage of evaluable patients with an improvement in VTT according to the Mayo classification (assessed using MRI abdomen scans at screening and week 9, prior to surgery. Secondary endpoints were percentage change in surgical approach, percentage change in VTT height, response rate (by RECIST) and evaluation of surgical morbidity assessed by Clavien-Dindo classification. Results: The percentage of evaluable patients with an improvement in VTT according to the Mayo classification was 26.58% [80% CI: 15.76%, 39.74%] (6 of 21 evaluable patients). 35.29% (6 of 17 patients who progressed to surgery) had a change in surgical approach to a less invasive option. There was a median percentage reduction in VTT height of 21.49% (SD=27.60%). The response rate (by RECIST) in the evaluable population was 61.90% SD, 14.29% PR, 9.52% PD. In terms of surgical morbidity 11.76% (2 of 17 patients who progressed to surgery) experienced a Clavien-Dindo 3 or greater complication (0 CD3, 1 CD4, 1 CD5). Conclusions: NAXIVA provides unique prospective data on the feasibility of neoadjuvant axitinib administration to down stage IVC VTT and reduce the extent of surgery. Work is ongoing to establish predictors of response. Clinical trial information: NCT03494816 .

scholarly journals A Case of Type 1 Papillary Renal Cell Cancer with Pelvic Tumor Thrombus Masquerading as Urothelial Cancer with Review of Literature

2019 ◽  
Vol 5 (4) ◽  
pp. 157-160
Author(s):  
Lalit Kumar ◽  
Siddharth Jain ◽  
Seema Kaushal ◽  
Amlesh Seth ◽  
Ritesh Goel ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Urothelial Cancer ◽  
Cell Cancer ◽  
Pelvic Tumor ◽  
Review Of Literature

scholarly journals The Clinical Importance of Tumor Thrombus in Internal Jugular Vein Related to Papillary Thyroid Cancer

2019 ◽  
pp. 1-4
Author(s):  
Nurcihan Aygun ◽  
Mehmet Uludag ◽  
Alper Ozel
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Internal Jugular Vein ◽  
Tumor Thrombus ◽  
Jugular Vein ◽  
Lung Metastases ◽  
Postoperative Treatment ◽  
Whole Body ◽  
Solid Organ ◽  
Papillary Thyroid

Objective: We aimed to present a case with a previous thyroid surgery, who developed an internal jugular vein thrombus due to papillary thyroid cancer (PTC) in the remnant tissue. Case: A 54-year-old female patient, with a previous subtotal thyroidectomy, presented with a mass on the left side of her neck. Thyroid ultrasound disclosed a heterogeneous nodule of 67x48x32 mm in the left thyroid lobe. An isoechoic tumor thrombus was observed extending intraluminally from the middle thyroid vein to the internal jugular vein. No lymph node or solid organ invasion were detected in the neck. Fine needle aspiration biopsy revealed cytological findings consistent with PTC. Total thyroidectomy, left sided central neck dissection and partial left jugular vein resection was performed. The pathologic examination revealed mid-differentiated unifocal encapsulated follicular variant of PTC. The whole-body scan performed after the postoperative treatment of 150 mCi of radioactive iodine, revealed multiple lung metastases. Conclusion: The presence of a tumor thrombus in the thyroid vein or internal jugular vein is strongly suspicious for malignancy even in the absence of malignant findings on cytology. It is an important finding that is highly suspicious for distant metastasis in the cytologically diagnosed patients.

scholarly journals Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report

2021 ◽  
Vol 37 ◽  
pp. 101660
Author(s):  
Andrea Benedetto Galosi ◽  
Alessio Papaveri ◽  
Daniele Castellani ◽  
Edoardo Agostini ◽  
Luciano Burattini ◽  
...  
Keyword(s):  
Case Report ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Tumor Thrombus ◽  
Cell Cancer ◽  
Lessons Learned ◽  
Metastatic Renal Cell Cancer ◽  
Level Ii

EXTENSION OF TUMOR THROMBUS TO INTERNAL JUGULAR VEIN IN FOLLICULAR THYROID CANCER

2004 ◽  
Vol 65 (1) ◽  
pp. 34-37 ◽  
Author(s):  
Takafumi SEKINO ◽  
Takuya YAMADA ◽  
Hisashi IWATA ◽  
Hiroshi MATSUO ◽  
Koyo SHIRAHASHI ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Internal Jugular Vein ◽  
Tumor Thrombus ◽  
Jugular Vein ◽  
Follicular Thyroid Cancer
Sign in / Sign up

Export Citation Format

Share Document